VRTX
Vertex PharmaceuticalsVertex Pharmaceuticals is a biotechnology name in the health care sector. Over the past year it returned +23.2%, against -3.6% over three months and -9.8% over one. It trades 6.3% above its 200-day average, so the longer trend is confirming recent strength. Annualized volatility of 28.6% is moderate by single-stock standards.
Its worst peak-to-trough decline over the year was -15.2%, and it has traded a median $564M a day, the figure that decides whether a position can actually be entered and exited at posted prices. Its daily moves correlate 0.23 with the S&P 500 proxy, so it has been moving substantially on its own.
How VRTX scores on all four profiles
Its standing on steadiness, defensiveness and rebound, plus the factor-by-factor breakdown behind each score, and its closest and least-correlated peers among 7 others in Biotechnology.
Start a free 7-day trial| 1 day | -0.2% |
| 1 week | -4.6% |
| 1 month | -9.8% |
| 3 months | -3.6% |
| 6 months | +15.9% |
| 1 year | +23.2% |
| 12-1 momentum | +36.5% |
| Volatility (1y, annualized) | 28.6% |
| Max drawdown (1y) | -15.2% |
| Distance vs 200-day average | +6.3% |
| Return per unit of risk | 0.81 |
| Median daily dollar volume | $564M |
Get VRTX when it shows up in a ranking
Two editions a weekday, free, ranked lists built from this same data, on whatever the market is talking about.
Everything on this page is computed from daily adjusted closing prices. It contains no earnings, balance-sheet, guidance or ownership data, and it is not a valuation. Nothing here is tailored to your circumstances or a recommendation to buy or sell. Past performance does not predict future results.